The U.S. poultry medicine market is experiencing robust expansion, valued at approximately $1.83 billion in 2024 and expected to reach $3.11 billion by 2033. This growth, driven by a compound annual growth rate of 6.2%, reflects increasing demand for poultry products and evolving practices in poultry health management.
Rising consumption and strong market performance have played a significant role in boosting the industry. The U.S. poultry sector continues to lead in both domestic and global meat markets, supported by efficient production methods, superior genetics, abundant feed supplies, and steady consumer demand. From 2013 to 2022, broilers made up the majority of poultry sales, with eggs and turkeys contributing smaller but notable shares.
As poultry consumption grows, so does the need for advanced and sustainable farming methods. Maintaining flock health has become a top priority, prompting a move away from traditional antibiotics and toward alternative health solutions. This shift is largely a response to growing public concern about antimicrobial resistance, leading to regulations that limit the use of medically important antibiotics in poultry farming.
Historically, antibiotics were used both to treat infections and promote growth in animals. However, projections show that antibiotic use in food animals could rise significantly worldwide by 2030. In response, the U.S. poultry industry is adopting new health strategies such as vaccines, probiotics, and plant-based supplements to support flock health without contributing to resistance.
Innovations in veterinary science and animal nutrition are also propelling the market forward. New technologies, including specialized vaccines, diagnostics, and feed additives, are equipping producers with better tools to manage disease, optimize productivity, and improve food safety. These advancements are helping the industry transition toward more resilient and environmentally responsible poultry farming practices.
